Halozyme Therapeutics | HALO - Equity Capital And Reserves



Halozyme Therapeutics reported $332.75M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 822.38M 57.14M Jun/2025
Agios Pharmaceuticals USD 1.37B 96.97M Jun/2025
Alnylam Pharmaceuticals USD 250.59M 135.16M Jun/2025
Amarin USD 473.69M 12.49M Mar/2025
Amgen USD 7.43B 1.22B Jun/2025
Baxter International USD 7.05B 90M Mar/2025
Cytokinetics USD -737440000 471.03M Jun/2025
DBV Technologies USD 86.22M 83.35M Jun/2025
Eli Lilly USD 18.27B 2.43B Jun/2025
Halozyme Therapeutics USD 332.75M 149.52M Jun/2025
Ionis Pharmaceuticals USD 631.72M 156M Jun/2025
MannKind USD -55042000 3.58M Jun/2025
Pfizer USD 88.7B 1.64B Jun/2025
United Therapeutics USD 7.17B 366.4M Jun/2025